Business
PreveCeutical Announces Canadian Patent Office Allowance of Innovative Pain Therapy Technology
Vancouver, British Columbia--(Newsfile Corp. - February 25, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Canadian Patent Office has allowed Canadian Patent Application No. 3127020, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This allowance represents a significant milestone in the protection of PreveCeutical's proprietary technologies aimed at addressing unmet needs
About this update from Preveceutical Medical Inc
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - February 25, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Canadian Patent Office has allowed Canadian Patent Application No. 3127020, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This allowance represents a significant milestone in the protection of PreveCeutical's proprietary technologies aimed at addressing unmet needs in pain management.","length":558,"tagName":"p"},{"type":"text","content":"The Canadian patent application is directed novel cyclized peptides that are analogues of dynorphin, an endogenous opioid peptide. These compounds are designed to deliver effective pain relief while potentially reducing the adverse effects commonly associated with traditional opioid therapies, such as dependence and tolerance. The invention also encompasses pharmaceutical compositions and methods of use for treating or preventing pain in subjects, reinforcing the therapeutic potential of this technology.","length":509,"tagName":"p"},{"type":"text","content":"This patent application is jointly owned by PreveCeutical Medical Inc. and The University of Queensland, reflecting the strength of the collaborative research partnership between the two organizations. Grant of the application is expected in Q2 2026 - the granted patent will provide exclusivity in Canada until January 2040, subject to maintenance, and forms part of a broader patent family with corresponding applications pending in the United States, Europe, and Australia. This global strategy ensures robust protection for PreveCeutical's intellectual property portfolio and supports its long-term commercialization objectives.","length":636,"tagName":"p"},{"type":"text","content":"PreveCeutical's pain therapy program focuses on developing next-generation peptide-based analgesics that aim to overcome the limitations of conventional opioids. By leveraging advanced peptide engineering and cyclization techniques, these candidates are designed to exhibit enhanced stability and receptor selectivity, which could significantly improve patient outcomes in managing acute and chronic pain.","length":409,"tagName":"p"},{"type":"text","content":"PreveCeutical's CEO, Stephen V...